The effects of alfaxalone on cardiac and pulmonary vascular size in cats evaluated by thoracic radiography and echocardiography.

Alfaxalone is a neuroactive steroid that modulates the GABA A receptor, which has shown recent widespread use as a sedative and anesthetic agent in cats, especially in patients being screened for cardiovascular disease. This prospective, partially blinded, randomized experimental study aimed to determine if sedation with alfaxalone would alter the appearance of the cardiac silhouette or pulmonary vasculature on thoracic radiographs or echocardiographic indices of cardiac or pulmonary vascular size. Eleven apparently healthy adult cats were recruited from a research colony. Four-view thoracic radiographs and an echocardiogram were performed at baseline and following a 5 mg/kg intramuscular dose of alfaxalone. Vertebral heart score (VHS) and cranial and caudal lobar pulmonary vascular measurements were obtained at both time points by two independent blinded observers, and these were analyzed using two-way ANOVA. The nonblinded echocardiographer obtained echocardiographic measurements at both time points, which were analyzed using a paired t-test or Wilcoxon signed rank test. No significant differences were identified in VHS measurements or echocardiographic parameters between baseline and sedated cats. In healthy cats, alfaxalone does not appear to significantly affect the cardiovascular structures evaluated via thoracic radiography or echocardiography.